- Our experience with the treatment of lanreotide in combination with everolimus in the treatment of Merkel cell carcinoma2013 | Publication without faculty affiliation
- Lanreotide autogel therapy in patients with acromegaly - current role and perspectives for the future2010 | First Faculty of Medicine
- Succes with lanreotide in treatment of thyroid-associated orbitopathy2003 | Central Library of Charles University, Second Faculty of Medicine
- Long-term treatment with lanreotide in patients with symptomatic neuroendocrine carcinoma2011 | First Faculty of Medicine
- Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone2011 | First Faculty of Medicine
- Combined treatment of acromegaly with lanreotide and terguride2000 | First Faculty of Medicine
- OLE study - Open Label Extension study phase Clarinet with lanreotide Autogel 120 mg in metastatic enteropancreatic neuroendocrine tumors2016 | First Faculty of Medicine
- Conservative treatment of pancreatico-cutaneous fistula using lanreotide and artificial nutritionPublication without faculty affiliation
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study2021 | First Faculty of Medicine
- Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study2016 | Faculty of Medicine in Pilsen
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension2010 | First Faculty of Medicine
- Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS studyPublication without faculty affiliation
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study2016 | First Faculty of Medicine
- A succesfull conservative treatment of traumatic lesion of the pancreatic duct2006 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport
- Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone2011 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- The ENETS Consensus Quidelines 2016 - somatostatin analogues in the treatment of neuroendocrine tumors2016 | First Faculty of Medicine
- No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly2008 | First Faculty of Medicine
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors2014 | First Faculty of Medicine
- Case report of a patient with advanced pancreatic neuroendocrine tumor2021 | Publication without faculty affiliation
- The treatment of pancreo-cutaneous fistula by canreotidePublication without faculty affiliation
- Preparation of 99m-Tc-labelled lanreotide for detection of somatostatin receptor-positive tumors2001 | Faculty of Pharmacy in Hradec Králové
- Lanreotide labeled with 99mTc: Preparation, preclinical testing and comparison with 111In-DTPA-octreotide2002 | Publication without faculty affiliation
- Regression of acromegalic left ventricular hypertrophy after lanreotide (a glow-release somatostatin analog)1999 | First Faculty of Medicine
- Lanreotide and enteral nutrition in home treatment of pancreaticocutaneous fistulaPublication without faculty affiliation
- Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide1994 | First Faculty of Medicine
- Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumoursPublication without faculty affiliation
- Infekce jaterních cyst u pacientů s ADPKD při terapii lanreotidem během multicentrické studie DIPAK-1 : komentář2017 | First Faculty of Medicine
- Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency2006 | First Faculty of Medicine
- Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency2006 | Faculty of Physical Education and Sport
- Comparable long-term efficacy of lanreotide and octreotide: Results of a 12-month observational study in acromegalyPublication without faculty affiliation